Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Enochian Biosciences Inc. stock logo
ENOB
Enochian Biosciences
$0.61
$0.39
$2.99
$40.80M1.09137,347 shs88,300 shs
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
$0.06
-7.7%
$0.33
$0.05
$68.00
$658K1.91.30 million shs19,409 shs
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
$0.37
-4.9%
$0.36
$0.22
$4.79
$15.42M-0.17830,629 shs299,126 shs
Orgenesis Inc. stock logo
ORGS
Orgenesis
$1.95
-2.5%
$2.28
$0.87
$10.80
$9.36M0.729,412 shs1,035 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Enochian Biosciences Inc. stock logo
ENOB
Enochian Biosciences
0.00%0.00%0.00%0.00%0.00%
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
-8.45%-15.80%-77.54%-99.08%-99.88%
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
+2.36%+7.91%-1.42%-15.86%-82.89%
Orgenesis Inc. stock logo
ORGS
Orgenesis
0.00%-0.50%-13.79%-60.08%+199,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Enochian Biosciences Inc. stock logo
ENOB
Enochian Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
0.4153 of 5 stars
0.05.00.00.00.00.00.6
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
2.5599 of 5 stars
3.14.00.00.03.00.01.3
Orgenesis Inc. stock logo
ORGS
Orgenesis
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Enochian Biosciences Inc. stock logo
ENOB
Enochian Biosciences
0.00
N/AN/AN/A
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
0.00
N/AN/AN/A
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
2.25
Hold$4.921,225.25% Upside
Orgenesis Inc. stock logo
ORGS
Orgenesis
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest LPTX, ORGS, HEPA, and ENOB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/27/2025
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Enochian Biosciences Inc. stock logo
ENOB
Enochian Biosciences
N/AN/AN/AN/A$1.37 per shareN/A
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
N/AN/AN/AN/A$1.29 per shareN/A
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
N/AN/AN/AN/A$2.35 per shareN/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
$662K14.14N/AN/A($6.58) per share-0.30
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Enochian Biosciences Inc. stock logo
ENOB
Enochian Biosciences
-$113.43MN/A0.00N/AN/AN/A-154.69%-130.66%N/A
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
-$48.93M-$219.00N/AN/AN/A-812.56%-207.31%8/11/2025 (Estimated)
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
-$81.41M-$1.70N/AN/AN/AN/A-116.24%-93.18%8/11/2025 (Estimated)
Orgenesis Inc. stock logo
ORGS
Orgenesis
-$55.36MN/A0.00N/A-3,827.81%N/A-130.18%8/6/2025 (Estimated)

Latest LPTX, ORGS, HEPA, and ENOB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
-$0.38-$0.37+$0.01-$0.37N/AN/A
3/26/2025Q4 2024
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
-$0.39-$0.37+$0.02-$0.37N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Enochian Biosciences Inc. stock logo
ENOB
Enochian Biosciences
N/AN/AN/AN/AN/A
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
N/AN/AN/AN/AN/A
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
N/AN/AN/AN/AN/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Enochian Biosciences Inc. stock logo
ENOB
Enochian Biosciences
N/A
0.33
0.33
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
N/A
1.30
1.30
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
N/A
3.97
3.97
Orgenesis Inc. stock logo
ORGS
Orgenesis
N/A
0.07
0.07

Institutional Ownership

CompanyInstitutional Ownership
Enochian Biosciences Inc. stock logo
ENOB
Enochian Biosciences
7.16%
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
17.24%
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
30.46%
Orgenesis Inc. stock logo
ORGS
Orgenesis
22.56%

Insider Ownership

CompanyInsider Ownership
Enochian Biosciences Inc. stock logo
ENOB
Enochian Biosciences
21.72%
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
4.70%
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
5.40%
Orgenesis Inc. stock logo
ORGS
Orgenesis
5.66%
CompanyEmployeesShares OutstandingFree FloatOptionable
Enochian Biosciences Inc. stock logo
ENOB
Enochian Biosciences
2258.28 million45.63 millionNot Optionable
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
2010.98 million6.63 millionNo Data
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
4041.44 million36.25 millionOptionable
Orgenesis Inc. stock logo
ORGS
Orgenesis
1504.80 million4.53 millionNo Data

Recent News About These Companies

Orgenesis (NASDAQ:ORGS) Shares Down 5.5% - Time to Sell?
Orgenesis Delays Filing of Quarterly Report
Orgenesis secures $5M equity investment from Williamsburg Venture
Orgenesis Inc. Reports Q3 2024 Financial Results
Orgenesis Provides Third Quarter 2024 Business Update
Orgenesis Expands Board with Three New Appointments
Orgenesis commences trading on OTCQX Best Market
Orgenesis Commences Trading on OTCQX® Best Market
45O.SG,0P0001J8IU,0 (45O.SG)
Why Orgenesis (ORGS) Stock Is Down 23% Today
Orgenesis Inc.: Orgenesis Announces Reverse Stock Split
Orgenesis Approves 1-for-10 Reverse Stock Split
Orgenesis Announces Reverse Stock Split
Is Orgenesis Stock (ORGS) a Good Investment?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Enochian Biosciences stock logo

Enochian Biosciences NASDAQ:ENOB

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer. The company's product pipeline includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a gene therapy curative treatment for HBV. It develops ENOB-DC-11, an allogeneic dendritic cell therapeutic vaccine for solid tumors; ENOB-DC-12-XX, allogeneic dendritic cell therapeutic vaccine for other solid tumors; and ENOB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. Enochian Biosciences, Inc. has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was incorporated in 2017 and is headquartered in Los Angeles, California.

Hepion Pharmaceuticals stock logo

Hepion Pharmaceuticals NASDAQ:HEPA

$0.06 -0.01 (-7.69%)
As of 12:43 PM Eastern

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Leap Therapeutics stock logo

Leap Therapeutics NASDAQ:LPTX

$0.37 -0.02 (-4.87%)
As of 01:20 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Orgenesis stock logo

Orgenesis NASDAQ:ORGS

$1.95 -0.05 (-2.50%)
As of 12:33 PM Eastern

Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.